Loading...
Philogen Community
BIT:PHIL Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
Community Investing Ideas
Analysts Maintain €26 Target for Philogen as Buyback and Valuations Remain Stable
Key Takeaways Advancing late-stage therapies and strategic pharma partnerships position Philogen for recurring product sales, stronger margins, and reduced funding risk through enhanced cash flow visibility. Alignment with personalized medicine trends and a robust cash position support long-term growth, innovation, and protection of shareholder value amid rising global demand for oncology solutions.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
€26
6.5% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
-8.58% p.a.
Profit Margin
8.28%
Future PE
250.25x
Share price in 2028
€33.46